Stroke, Volume 54, Issue Suppl_1, Page ATMP108-ATMP108, February 1, 2023. Introduction:Sleep apnea, a very common condition among post-stroke patients, is associated with worse functional, cognitive, and neurological outcomes after stroke. Little is known about the association between change of sleep apnea and changes in outcome over time.Methods:Associated with the Brain Attack Surveillance in Corpus Christi (BASIC) project, ischemic stroke patients (2016-2019) were offered sleep apnea testing with a portable respiratory monitor (ApneaLink Plus) shortly after stroke and at 3, 6, and 12 months post-stroke. Sleep apnea was quantified using the respiratory event index (REI), the number of apneas plus hypopneas per recording hour. At 3, 6, and 12-months post-stroke, functional outcome was assessed using activities of daily living (ADL)/instrumental activities of daily living (IADL) score (1-4, lower better); cognitive outcome was assessed using the Modified Mini-Mental State Examination (3MS) (0-100, higher better); neurological outcome was assessed using the NIHSS (0-42, lower better). Multivariate mixed models were fitted under a Bayesian approach to obtain random slopes in REI over time and the three outcomes (1-unit change in outcome per month), adjusted for age, sex, ethnicity, pre-stroke function and cognitive status, education, marital status, stroke history, tpa use, recurrent stroke, and depression. Linear regression models assessed the association between random slope of REI and random slopes of the three outcomes.Results:Of the 482 Mexican American or non-Hispanic white participants with at least one REI measurement, in fully adjusted models, improvement in sleep apnea was significantly associated with improvement in NIHSS (0.0094 (95% CI: 0.0070, 0.0118)) but not with changes in ADL/IADL or 3MS.Conclusions:Improvement in sleep apnea paralleled improvement in neurological status over the first year after stroke.
Risultati per: Prima terapia farmacologica per l’apnea notturna (OSAS)
Questo è quello che abbiamo trovato per te
Abstract TP197: Obstructive Sleep Apnea Associated With Lower All-Cause Mortality In Ischemic Stroke Patients
Stroke, Volume 54, Issue Suppl_1, Page ATP197-ATP197, February 1, 2023. Introduction:Obstructive sleep apnea (OSA) is a sleep disorder associated with cardiovascular risk factors similar to those associated with cerebral infarction (CI). Our aim was to characterize patient demographics and to investigate the effect of OSA in CI.Methods:Retrospective cohort study using 2019 National Inpatient Sample. Adults with diagnoses of CI and OSA were included. Primary outcome was all-cause mortality, and secondary outcomes were length of stay (LOS) and total charge in USD.Results:Out of 700175 CI patients, 49735 had OSA. Compared to Non-OSA-CI cohort, OSA-CI cohort were younger (67.38 vs 69.67 years,p
Terapia del paziente con Ipercolesterolemia (età > 40 anni)
Tumore al seno, una nuova terapia a bersaglio molecolare
Messa a punto all’IRCCS IRE, in laboratorio fa regredire malattia
Una guida per i medici di medicina generale per la terapia domiciliare del paziente Sars-Cov-2 positivo
L’Assimefac annuncia la pubblicazione della guida per i medici di medicina generale in merito alla terapia domiciliare del paziente Sars-Cov-2.
Menopausa, terapia ormonale può aiutare contro l'Alzheimer
Nelle donne è associata a migliore memoria e capacità cognitive
Home Sleep Apnea Testing for the Diagnosis of Obstructive Sleep Apnea
A 50-year-old patient with epilepsy, hypertension, loud snoring, recent 50-lb weight gain, and abrupt awakenings with a feeling of breathlessness but no headaches or excessive daytime sleepiness presented with concerns. What would you do next?
Ipertensione correlata alla terapia del cancro
A Parma una nuova terapia per incompatibilità Rh madre-feto
Senza trasfusioni in utero, ripulito sangue della mamma
Da Ema via libera a prima terapia genica per emofilia B
Colpisce 1 su 20.000-50.000 neonati maschi, cura con 1 infusione
Potenziale terapia per il cancro del colon metastatico
Talassemia, con la terapia genica stop a trasfusioni
Per 89% pazienti, dopo 3 anni. Locatelli, con una sola infusione
Linfoma, funziona trattamento iniziale con terapia Car-T
Per neoplasia a grandi cellule b recidivante o refrattaria